GeneCellNano Flagship is a pioneering brand that focuses on developing new biological drugs, biomarkers, and diagnostics for diseases with unmet clinical needs. With a strong emphasis on research and innovation, their team of top researchers specializes in biological Advanced Therapy Medicinal Products (ATMP) and nanotechniques. The brand's primary objective is to address cardiovascular diseases, age-related macular degeneration, brain, ovarian, and bladder cancer by creating new treatments.

Collaborating with clinical actors, leading companies, and third sector players, GeneCellNano Flagship aims to establish an ecosystem that combines public and private entities, positioning itself as an international leader in the rapidly expanding sector. By integrating innovative research, advanced production techniques, substantial clinical experience, and an extensive international network, the brand seeks to secure substantial domestic and foreign funding for gene, cell, and nanotechnology. Ultimately, their goal is to introduce effective treatments for severe chronic diseases, create new jobs, and contribute to the economic welfare of Finnish society.

GeneCellNano also delves into gene therapy and cell therapy research lines. The former focuses on addressing key challenges in gene therapy, such as immune responses, achieving cell-specific transduction, and targeting transgene integration. On the other hand, the cell therapy line aims to develop more efficient transduction methodologies for NK cells, create proprietary NK cell processes, and design CARs for controlling NK cell activity.

Additionally, GeneCellNano's nanotechnology research line aims to develop technology platforms for the localized and controlled delivery of biologicals to cardiac, retinal, and oncological targets. Their innovative platforms include controlled release systems, nanomedicines with improved intracellular disposition, and nanomedicines and extracellular vesicles for cell-specific delivery properties.

To get in touch with GeneCellNano, contact [email protected] or visit their website for more information.